On October 9th, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) presented a poster with accumulative updates from its Phase I/II trial results of investigational, targeted cancer …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase-positive (ALK+) advanced …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its partner Otsuka Pharmaceutical Co.
In a research report released on Monday, Leerink top analyst Michael Schmidt initiated coverage on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) with a price …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) …
In a research report released Friday, Cowen analyst Chris Shibutani reiterated an Outperform rating on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) with a price …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the second quarter and first half of 2016, including revenue from sales of Iclusig® (ponatinib).
Analysts maintain bullish stances on biotech companies Opko Health Inc. (NYSE:OPK) and Ariad Pharmaceuticals, Inc.
Pipeline updates from biotech companies Cerus Corporation (NASDAQ:CERS) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) cause analysts to reiterate Buy ratings on both, highlighting various …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the initiation of a New Drug Application (NDA) submission for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to …
